Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT.

[1]  P. Veit-Haibach,et al.  Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE , 2021, The Journal of Nuclear Medicine.

[2]  G. Antoch,et al.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient , 2020, BMC Cancer.

[3]  Ezgi Ilan,et al.  Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE , 2019, The Journal of Nuclear Medicine.

[4]  T. Ohlsson,et al.  A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors , 2019, The Journal of Nuclear Medicine.

[5]  Li Zhang,et al.  111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden , 2019, The Journal of Nuclear Medicine.

[6]  M. Hansmann,et al.  Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors , 2018, Scientific Reports.

[7]  S. Deppen,et al.  68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis , 2016, The Journal of Nuclear Medicine.

[8]  T. Holland-Letz,et al.  SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors , 2014, Molecular Imaging and Biology.

[9]  H. Dittmann,et al.  Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? , 2014, Diagnostic and interventional imaging.

[10]  M. Lubberink,et al.  Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification , 2014, The Journal of Nuclear Medicine.

[11]  P. Cumming,et al.  68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.

[12]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy , 2009, Journal of Nuclear Medicine.

[13]  Markus Jahn,et al.  Processing of Generator-Produced 68Ga for Medical Application , 2007, Journal of Nuclear Medicine.

[14]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[16]  R. Bale,et al.  Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .